Is West Pharmaceutical Services (WST) a risky stock?
As of July 21, 2026, Clavix grades West Pharmaceutical Services (WST) A- for risk, a composite score of 82 out of 100 on an A+ to F scale, which puts WST in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind WST's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how WST scores on each, as of July 21, 2026.
What's moving WST's risk right now
Company-specific signals Clavix flags behind WST's current grade, drawn from recent news and filings as of July 21, 2026.
Despite strong recent price appreciation driven by solid quarterly results, investors should exercise caution as the headline indicates underlying risks remain that could challeng…
DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.
What a A- grade means
On the Clavix A+ to F scale, WST's composite of 82 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell WST or any security. Grades are risk indicators, not predictions of return. Data may be delayed.